Loading...
•
Jun 30, 2024
Celsion Q2 2024 Earnings Report
IMUNON reported second quarter financial results and provided a business update.
Key Takeaways
IMUNON reported a net loss of $4.8 million for the second quarter of 2024. The company announced positive topline results from the Phase 2 OVATION 2 Study with IMNN-001 in advanced ovarian cancer and plans to hold an End-of-Phase 2 meeting with the FDA to clarify the path to a Phase 3 pivotal study.
Reported positive topline results from the Phase 2 OVATION 2 Study with IMNN-001 in advanced ovarian cancer, showing overall survival of more than 11 months compared to standard-of-care.
Plans to hold an End-of-Phase 2 meeting with the FDA to clarify the path to a Phase 3 pivotal study for IMNN-001.
Received approximately $9.3 million in net proceeds from a capital raise, supporting the initiation of a planned Phase 3 study of IMNN-001.
First participants vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial.
Celsion
Celsion
Forward Guidance
IMUNON believes it has sufficient capital resources to fund its operations into the third quarter of 2025.